MannKind | MNKD - Ebitda





Ebitda Veränderung Datum
Adma Biologics USD 61.07M 12.52M 2026-03
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Eli Lilly USD 10.29B 1.86B 2026-03
Halozyme Therapeutics USD 328.81M 109.24M 2026-06
Insmed USD -148.3M 165.88M 2026-03
Karyopharm Therapeutics USD -26.2M 1.83M 2024-09
MacroGenics USD -30.2M 52.15M 2026-03
MannKind USD 2.93M 5.98M 2026-03
Merck USD -1.54B 7.84B 2026-03
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Novavax USD 19.36M 190.79M 2025-12
Novo Nordisk DKK 37.36B 31.84B 2026-06
Pfizer USD 6.01B 18M 2026-06
Sanofi EUR 3.69B 375M 2026-06
Xencor USD -34.63M 86.74M 2026-06